Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. (November 2018)

• Record Type: Journal Article
• Authors: Hauswald, H.; Jensen, A.D.; Krauss, J.; Haselmann, R.; Lossner, K.; Hartmann, S.; Windemuth-Kieselbach, C.; Münter, M.W.; Debus, J.
• Is Part Of: Clinical and translational radiation oncology. Volume 13(2018)
• Page Start: 64
• Page End: 73
• Publication Date: 2018-11
• Subjects: Particle therapy -- Carbon ion therapy -- Cetuximab -- LAHNC -- SCCHN -- Head and neck cancer; Cancer -- Radiotherapy -- Periodicals; Oncology -- Periodicals; Cancer -- Radiotherapy; Oncology; Radiation Oncology; Neoplasms -- radiotherapy; Translational Medical Research; Periodicals; Electronic journals; Periodicals; 616.9940642
• DOI: 10.1016/j.ctro.2018.09.005
• Languages: English
• ISSNs: 2405-6308

Abstract

Highlights: Trimodal approach with carbon ions was tolerable and promising. No high-grade radiation adverse events were documented. No adverse events resulted in death of patients. Quality of life recovered for most aspects until the last follow-up visit. Abstract: Purpose: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx. Methods: In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm consisted of a combined induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, followed by bioradiation with the monoclonal antibody cetuximab, carbon ion boost (24Gy(RBE) in 8 fractions) and IMRT (50 Gy in 25 fractions). The trial was closed early due to slow accrual. Results: Eight patients (median age 52.5 years) were enrolled into the trial. The median follow-up was 13 months and the 12-months locoregional tumor control, progression-free survival and overall survival rates were 100.0% each. Complete remission was achieved in 7 patients. The most commonly late radiation adverse event was xerostomia (85.7% at 12 months). Five serious adverse events with recovery were documented in 4 patients: mucositis grade 3 (n = 2), decreased lymphocyte count grade 4, febrile neutropenia grade 4 and hypersensitivity grade 3 to cetuximab (n = 1 each). Most symptom scales had their worst value at the last treatment day and recovered until the 4th follow-up visit. Conclusion: The study treatment was tolerable and promising. Reduced quality of life recovered for most aspects until the last follow-up visit.